Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Outcomes and options for R/R AML patients who fail venetoclax-based salvage therapy

Andrius Žučenka • 7 Jun 2021
EHA 2021
Acute Myeloid Leukemia Leukemia Cytarabine Glasdegib Venetoclax

Andrius Zucenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses outcomes for patients with relapsed/refractory (R/R) acute myeloid leukemia (AML) who fail venetoclax-based salvage therapies, commenting on poor prognosis. Dr Zucenka reports that venetoclax re-initiation or low-dose cytarabine plus glasdegib may be possible options for patients in this subgroup. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Explore the AML Channel banner with headshots of Naval Daver, Eunice Wang, and Thomas Cluzeau

More from Andrius Žučenka

ARCHIVE conditioning enables direct-to-transplant strategy in high-risk AML
3:16
ARCHIVE conditioning enables direct-to-transplant strategy in high-risk AML
Andrius Žučenka • 14 Jun 2026
Revumenib after transplant shows promise in KMT2A-rearranged and NPM1-mutated AML
2:57
Revumenib after transplant shows promise in KMT2A-rearranged and NPM1-mutated AML
Andrius Žučenka • 14 Jun 2026
Venetoclax combinations show high remission rates in FLT3- and IDH1-mutated AML
3:57
Venetoclax combinations show high remission rates in FLT3- and IDH1-mutated AML
Andrius Žučenka • 14 Jun 2026
ARCHIVE conditioning for upfront alloSCT in active AML and high-risk MDS-IB2
5:59
ARCHIVE conditioning for upfront alloSCT in active AML and high-risk MDS-IB2
Andrius Žučenka • 6 Jan 2026

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals